Comparison of the use of rhBMP-7 versus iliac crest autograft in single-level lumbar fusion: a meta-analysis of randomized controlled trials.
The aim of this study was to evaluate the safety and clinical effectiveness of rhBMP-7 (or osteogenic protein-1) versus that of autogenous iliac crest bone graft (ICBG) in single-level posterolateral fusion (PLF) of the lumbar spine. A systematic search of all articles published through July 1, 2016 was conducted in databases such as PubMed, EMBASE, Scopus, and the Cochrane Collaboration Library. Randomized controlled trials (RCTs) that compared rhBMP-7 with ICBG for the treatment of single-level degenerative spondylolisthesis, provided the fusion rate, clinical success rate, safety and adverse events report, operation time, and hospital stay durations as the outcome were assessed. As a result, a total of five RCTs involving 539 patients met the inclusion criteria. The outcomes of subgroup analysis demonstrated that when compared with autogenous ICBG, rhBMP-7 appear to yield lower fusion rates in instrumented posterolateral fusion patients (RR = 0.76, 95% CI [0.60, 0.98], P = 0.03), despite the test for overall fusion rates suggested that there was no significant difference between the two groups (RR = 0.89, 95% CI [0.78, 1.02], P = 0.09). Patients treated with OP-1 had shorter operation times versus those treated with ICBG (WMD = -16.70,95% CI [-25.83, -7.57], P = 0.0003). Additionally, the outcomes demonstrated a lack of significant differences between rhBMP-7 and ICBG in terms of clinical success of ODI, overall adverse events, revision rates and duration of hospitalization. In conclusion, with the exception of reducing the operation time, our review suggests that the use of the rhBMP-7 instead of ICBG produce no any additional beneficial effect on the fusion rates, clinical success of ODI, overall adverse events, revision rates and duration of hospitalization in single level PLF. On the contrary, it appeared to yield lower fusion rate in the instrumented posterolateral fusion patients and cannot be recommended as an effective tool for this set of patients.
Department of Orthopaedic, Fujian Provincial Hospital, Provincial Clinical Medical College Affiliated to Fujian Medical University, 134 East Street, Fuzhou, 350001, Fujian, People's Republic of China.
Fubiao
F
Ye
Department of Orthopedics, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, 362000, China.
Zhiyuan
Z
Zeng
Department of Orthopaedic, First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China.
Jianru
J
Wang
Department of Orthopaedic, First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China.
Hui
H
Liu
Department of Orthopaedic, First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China. wangxucheng@gmail.com.
Hua
H
Wang
Department of Orthopaedic, First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Second Road, Guangzhou, 510080, People's Republic of China. zhengzhmin@163.com.
Zhaomin
Z
Zheng
D000328:Adult; D000368:Aged; D064592:Autografts / Q000187:drug effects / Q000637:transplantation*; D016063:Blood Loss, Surgical; D055419:Bone Morphogenetic Protein 7 / Q000494:pharmacology*; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D007085:Ilium / Q000637:transplantation*; D007902:Length of Stay; D008159:Lumbar Vertebrae / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D061646:Operative Time; D017594:Publication Bias; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000494:pharmacology*; D012086:Reoperation; D013123:Spinal Fusion / Q000009:adverse effects; D016896:Treatment Outcome
C525819:BMP7 protein, human; D055419:Bone Morphogenetic Protein 7; D011994:Recombinant Proteins
Posterolateral spine fusion; Randomized controlled trial; Recombinant human bone morphogenetic protein-7; Systematic review